Radioligand Therapy (RLT) Companies

The global radioligand therapy market is projected to reach USD 10.91 billion by 2035 from USD 3.15 billion in 2025, at a CAGR of 13.2% during the forecast period. The growth of the radioligand therapy market is driven by the increasing global prevalence of cancer and the rising focus on oncology therapeutics.

Several key players in the radioligand therapy industry with a strong global footprint include Novartis (Switzerland), Bayer (Algeta) (Germany), Curium Pharma (France), Eli Lilly & Co. (Point Biopharma) (US), AstraZeneca (Fusion Pharmaceuticals Inc.) (UK), Progenics (Lantheus) (US), Ariceum Therapeutics (Germany), Telix Pharmaceuticals (Australia), ITM Isotope Technologies Munich SE (Germany), Convergent Therapeutics Inc. (US), Orano SA (France), Actinium Pharmaceuticals Inc. (US), Perspective Therapeutics (US), Clarity Pharmaceuticals (Australia), and Radiopharm Theranostics Ltd. (Australia). Companies in this sector employ various growth strategies to strengthen their international presence and reinforce market positions.

To know about the assumptions considered for the study download the pdf brochure

In March 2025, Novartis received the FDA approval for Pluvicto, indicated for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with an androgen receptor pathway inhibitor (ARPI) therapy.

Novartis (Switzerland)

Novartis (Switzerland) is a global pharmaceutical leader and one of the pioneers in advancing radioligand therapy (RLT). The company has played a pivotal role in shaping this therapeutic area by developing innovative targeted radioligand therapies that combine precision medicine with nuclear medicine to treat cancers. Novartis’ flagship products include Lutathera (lutetium Lu 177 dotatate), approved for gastroenteropancreatic neuroendocrine tumors, and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), approved for metastatic castration-resistant prostate cancer (mCRPC). These therapies mark significant milestones in the treatment of hard-to-treat tumors and highlight Novartis’ expertise in theranostics, wherein diagnostic imaging guides therapy selection.

Bayer (Germany)

Bayer has established a strong presence in the radioligand therapy (RLT) market by acquiring Algeta in 2014. This acquisition gave Bayer complete control of Xofigo (radium-223 dichloride), the first alpha-emitting radiopharmaceutical approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. Xofigo represented a groundbreaking advancement in nuclear medicine by offering targeted alpha therapy (TAT), which delivers highly localized radiation to bone metastases while minimizing damage to surrounding tissues. Bayer continues to build on this foundation by advancing research collaborations and expanding its radiopharmaceutical pipeline to address additional cancers. With its oncology and nuclear medicine expertise, Bayer remains a key innovator in the RLT field, working on both monotherapy & combination approaches to enhance clinical outcomes.

Market Ranking

The radioligand therapy market is characterized by intense consolidation, with key players commanding a substantial share of global revenues, estimated to be between 95% to 98% of the total market. These leading companies reinforce their market positions through strategic investments, regulatory advancements, and extensive partnerships. Notably, Novartis (Switzerland) is a global leader in radioligand therapy. Lutathera and Pluvicto set new standards for treating neuroendocrine tumors and metastatic prostate cancer, while ongoing investments expand their pipeline and global manufacturing capacity. Bayer (Germany), through its acquisition of Algeta, brought Xofigo (radium-223), the first FDA-approved alpha-emitting radiopharmaceutical for prostate cancer with bone metastases, and continues advancing targeted alpha therapy programs. Another key player like Curium Pharma (France), long established in nuclear medicine diagnostics, has expanded into therapeutics, building a pipeline of RLT candidates targeting prostate cancer and neuroendocrine tumors, supported by its strong global production and distribution infrastructure.

Furthermore, Eli Lilly & Co. (US), via its acquisition of Point Biopharma, entered the RLT market with promising late-stage candidates like PNT2002 for prostate cancer and PNT2003 for neuroendocrine tumors, strengthening its oncology portfolio. Moreover, through Fusion Pharmaceuticals, AstraZeneca (UK) is developing novel targeted alpha therapies, leveraging actinium-225 and antibody-based delivery systems, positioning itself as a key innovator in next-generation radioligand therapies for oncology.

The radioligand therapy (RLT) market is advancing rapidly with investments in isotope production, targeted ligands, and theranostic platforms that combine imaging and treatment. Precision oncology applications are driving adoption, particularly in prostate and neuroendocrine cancers. The market further strengthens favorable regulatory support, expanding reimbursement models, and strategic M&A activity. With rising innovation in alpha therapies and AI-driven design, RLT presents high growth opportunities for pharma leaders and emerging biotech firms.

The remainder of the market, comprising approximately 2–5%, is populated by various regional players. During the forecast period, these players are gaining ground through partnerships, collaborations, technological innovation, and approval of novel radioligand therapies. Market shifts are driven by advances in pharmaceutical contract manufacturing, changing regulatory landscapes, and growing demand for non-invasive, personalized medicine.

Related Reports:

Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com